Connection

Co-Authors

This is a "connection" page, showing publications co-authored by LEONID METELITSA and AMY COURTNEY.
Connection Strength

2.887
  1. Natural killer T cells and other innate-like T?lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood. 2023 02 23; 141(8):869-876.
    View in: PubMed
    Score: 0.881
  2. Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2024 Apr; 30(4):1210.
    View in: PubMed
    Score: 0.238
  3. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
    View in: PubMed
    Score: 0.224
  4. Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-a triggers tumorigenic inflammation in neuroblastoma. J Immunother Cancer. 2023 03; 11(3).
    View in: PubMed
    Score: 0.220
  5. LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells. Cancer Immunol Res. 2023 02 03; 11(2):171-183.
    View in: PubMed
    Score: 0.219
  6. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
    View in: PubMed
    Score: 0.187
  7. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
    View in: PubMed
    Score: 0.173
  8. IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol. 2018 10 01; 201(7):2141-2153.
    View in: PubMed
    Score: 0.161
  9. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
    View in: PubMed
    Score: 0.138
  10. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33.
    View in: PubMed
    Score: 0.121
  11. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2024 Nov 27.
    View in: PubMed
    Score: 0.062
  12. Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. 2024 Apr 03.
    View in: PubMed
    Score: 0.059
  13. A Nanoradiomics Approach for Differentiation of Tumors Based on Tumor-Associated Macrophage Burden. Contrast Media Mol Imaging. 2021; 2021:6641384.
    View in: PubMed
    Score: 0.049
  14. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
    View in: PubMed
    Score: 0.044
  15. Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res. 2014 Nov 01; 74(21):6260-70.
    View in: PubMed
    Score: 0.031
  16. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 2013 Jul 01; 73(13):4134-46.
    View in: PubMed
    Score: 0.028
  17. C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes. Chembiochem. 2012 Aug 13; 13(12):1733-7.
    View in: PubMed
    Score: 0.026
  18. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.